Also known as: Tricyclics
Tricyclic antidepressants (TCAs) predate SSRIs and remain in use for depression, chronic pain, migraine prevention, and some sleep conditions. Nearly all TCAs are cleared by CYP2D6 and CYP2C19, often in sequence: one enzyme produces an active metabolite, the other clears it. That means TCA dosing is uniquely sensitive to pharmacogenetic variation, and both CPIC and the FDA publish phenotype-based dose guidance.
Each link goes to the drug's full pharmacogenetics page with CPIC and FDA phenotype recommendations.
Combined products and brand names for the medications above. Each links to a pharmacogenetic breakdown.
This page covers the pharmacogenetics of tricyclic antidepressants in general. A Gene2Rx report tells you how your personal genotype interacts with every drug on this page.
Get your report Look up a medicationInformational only, not medical advice. Pharmacogenetic guidelines describe population-level patterns that inform prescribing decisions. Never start, stop, or change a medication without talking to your prescribing clinician.